Compare Intuit Inc. (INTU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Intuit Inc. trades at $333.31 (market cap $91.48B), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B). The key difference: Intuit Inc. is far larger — about 51.4× Recursion Pharmaceuticals Inc's market cap, and Intuit Inc. pays a 1.44% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INTU | RXRX | |
|---|---|---|
Market Cap | $91.48B | $1.78B |
Sector | Technology | Health |
52-Week High | $717.21 | $6.79 |
52-Week Low | $255.07 | $2.84 |
Enterprise Value | $89.94B | $1.30B |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $336.44, up 3.44% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $18.83B in 2025, with a net income margin of 20.54%, while analyst consensus is a Buy with a $401 price target. However, recent news highlights a 20% stock drop and securities fraud investigations related to TurboTax pricing issues, creating near-term uncertainty.
The outlook is mixed: strong fundamentals and AI-driven growth in financial software support upside, but legal risks and investor sentiment pressure pose challenges. Valuation metrics like a P/E of 20.4 appear reasonable if execution continues, yet volatility may persist until legal concerns resolve.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
